E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Plaque psoriasis |
Psoriasis en placas |
|
E.1.1.1 | Medical condition in easily understood language |
Psoriasis looks like red, raised, scaly areas of the skin. |
La psoriasis parece como zonas rojas, engrosadas, escamosas de la piel. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10050576 |
E.1.2 | Term | Psoriasis vulgaris |
E.1.2 | System Organ Class | 100000004858 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the proportion of patients achieving a DLQI 0/1 response at Week 16 in 3 pre defined subpopulations and in the overall study population. |
Evaluar la proporción de pacientes que alcanza una respuesta del DLQI de 0/1 en la semana 16 en las tres subpoblaciones definidas previamente y en la población global del estudio. |
|
E.2.2 | Secondary objectives of the trial |
To assess: - The proportion of patients achieving a DLQI 0/1 response at Week 52 in 3 pre defined subpopulations and in the overall study population. - The effects of treatment with secukinumab 300 mg with respect to changes in EQ-5D©, HAQ©-DI, NRS, TSQM and PBI response over time up to Week 16 and Week 52 compared to baseline in 3 pre-defined subpopulations and in the overall study population. - The proportion of patients achieving PASI 50, PASI 75, PASI 90, PASI 100 and IGA mod 2011 0/1 responses at Week 16 and Week 52 in 3 pre-defined subpopulations and in the overall study population. - The proportion of patients with DLQI scores 2-5, 6-10, 11-20, 21-30 at Week 16 and Week 52 compared to Baselinein 3pre-defined subpopulations and in the overall study population. - The overall safety and tolerability of treatment with secukinumab 300 mg in 3 pre-defined subpopulations and in the overall study population. |
Evaluar: - La proporción de pacientes que alcanza una respuesta del DLQI de 0/1 en la semana 52 en las 3 subpoblaciones predefinidas y en la población global del estudio. - El efecto del tratamiento con secukinumab 300 mg en relación con los cambios en la respuesta al EQ-5D©, ID-HAQ©, EVN, TSQM y PBI hasta la semana 16 y 52 respecto a la visita basal en las 3 subpoblaciones predefinidas y en la población global del estudio. - La proporción de pacientes que alcanzan PASI 50, PASI 75, PASI 90, PASI 100 y respuestas IGA mod. 2011 de 0/1 en las semanas 16 y 52 en las 3 subpoblaciones predefinidas y en la población global del estudio. - La proporción de pacientes con puntuaciones del DLQI de 2-5, 6-10, 11-20, 21-30 en las semanas 16 y 52 respecto a la visita basal en las 3 subpoblaciones predefinidas y en la población global del estudio. - La seguridad y la tolerabilidad del tratamiento con secukinumab 300 mg en las 3 subpoblaciones predefinidas y en la población global del estudio. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Men or women aged at least 18 years at time of Screening. - Moderate to severe plaque-type psoriasis diagnosed for at least 3 months prior to Screening and candidate for systemic therapy. - Other protocol defined inclusion criteria may apply. Please refer to the protocol. |
- Hombres o mujeres de al menos 18 años de edad en el momento de la selección. - Psoriasis en placas de moderada a grave diagnosticada al menos tres meses antes de la selección y candidatos a tratamiento sistémico. - Se pueden aplicar otros criterios de inclusión definidos en el protocolo. Por favor consulten el protocolo. |
|
E.4 | Principal exclusion criteria |
- Forms of psoriasis other than moderate to severe plaque-type psoriasis, e.g. drug-induced psoriasis at Screening. - Patients with previous treatment with any agent targeting interleukin (IL)-17 directly or IL-17 receptor A (e.g. secukinumab, ixekizumab, or brodalumab). - Pregnant or nursing (lactating) women - Women of child-bearing potential unless they use effective contraception - Other protocol-defined exclusion criteria may apply. Please refer to the protocol. |
- Formas de psoriasis diferentes a la psoriasis en placas de moderada a grave, p. ej., psoriasis inducida por fármacos en la selección. - Pacientes con tratamiento previo con cualquier fármaco dirigido directamente a la interleuquina (IL)-17 o al receptor A de la IL-17 (p. ej., secukinumab, ixekizumab o brodalumab). - Mujeres embarazadas o en periodo de lactancia - Mujeres en edad fértil salvo que esté utilizando métodos anticonceptivos eficaces - Se pueden aplicar otros criterios de exclusión definidos en el protocolo. Por favor consulten el protocolo. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
DLQI 0/1 response |
Respuesta de DLQI de 0/1 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
DLQI 0/1, EQ-5D, HAD-DI, NRS, TSQM, PBI, PASI 50/75/90/100, IGA mod 2011 0/1 response |
Respuesta DLQI 0/1, EQ-5D, HAD-DI, NRS, TSQM, PBI, PASI 50/75/90/100, IGA mod 2011 0/1 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
week 16 - week 52 |
semana 16 - semana 52 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 52 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 235 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
European Union |
Israel |
Russian Federation |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
última visita del último paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 24 |